Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome-Alzheimer's disease
Clíona FarrelliD, Yazead BuhidmaiD, Paige MumfordiD, Wendy HeywoodiD, Jenny HällqvistiD, Lisi Flores AguilariD, Elizabeth J. AndrewsiD, Negin Rahimzadah, Orjona Stella TasoiD, Eric W. Doran, Vivek SwarupiD, Elizabeth HeadiD, Tammaryn LashleyiD, Kevin A. MillsiD, Christina E. ToomeyiD, Frances K. WisemaniD
Abstract
Trisomy of chromosome 21, the cause of Down syndrome (DS), is the most commonly occurring genetic cause of Alzheimers disease (AD). Here, we compare the frontal cortex proteome of people with Down syndrome-Alzheimers disease (DSAD) to demographically matched cases of early-onset AD and healthy ageing controls. We find wide dysregulation of the proteome, beyond proteins encoded by chromosome 21, including an increase in the abundance of the key AD-associated protein, APOE, in people with DSAD compared to matched cases of AD. To understand the cell types that may contribute to changes in protein abundance, we undertook a matched single-nuclei RNA-sequencing study, which demonstrated that APOE expression was elevated in subtypes of astrocytes, endothelial cells and pericytes in DSAD. We further investigate how trisomy 21 may cause increased APOE. Increased abundance of APOE may impact the development of, or response to, AD pathology in the brain of people with DSAD, altering disease mechanisms with clinical implications. Overall, these data highlight that trisomy 21 alters both the transcriptome and proteome of people with DS in the context of AD, and that these differences should be considered when selecting therapeutic strategies for this vulnerable group of individuals who have high-risk of early-onset dementia.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 9
- FWCI
- 5.79
- Field percentile
- top 3%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Trisomy 21 cerebral organoids exhibit Alzheimer's disease amyloid and apolipoprotein E co-pathologies
Breanna R. Dooling, Anne Vielle, … Noah R. Johnson·bioRxiv·Jul 7, 2026
- Genetic mapping of APP and amyloid-β biology modulation by trisomy 21
Paige Mumford, Justin Tosh, … Frances K. Wiseman·Journal of NeurosciencePeer-reviewed·Jul 14, 2022
- Ts65Dn synaptic proteome partially recapitulates AD biochemical signature
Macarena Gómez de Salazar·bioRxiv·Apr 25, 2023
- Genetic dissection of Down syndrome-associated alterations in APP/amyloid-β biology using mouse models
Justin Tosh, Elena R. Rhymes, … Robert C. Wykes·Scientific ReportsPeer-reviewed·Mar 11, 2021
- Amyloid accumulation drives proteome-wide alterations in mouse models of Alzheimers disease like pathology
Jeffrey N. Savas, Yizhi Wang, … John R. Yates·Cell ReportsPeer-reviewed·Nov 1, 2017
- Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene-dose-sensitive AD-suppressor in human brain
Ivan Alić, Pollyanna Agnes Goh, … Henrik Zetterberg·Molecular PsychiatryPeer-reviewed·Jul 9, 2020